Literature DB >> 26372300

SERIAL NECK ULTRASOUND IS MORE LIKELY TO IDENTIFY FALSE-POSITIVE ABNORMALITIES THAN CLINICALLY SIGNIFICANT DISEASE IN LOW-RISK PAPILLARY THYROID CANCER PATIENTS.

Samantha Peiling Yang, Ariadne M Bach, R Michael Tuttle, Stephanie A Fish.   

Abstract

OBJECTIVE: American Thyroid Association (ATA) low-risk papillary thyroid cancer (PTC) patients without structural evidence of disease on initial posttreatment evaluation have a low risk of recurrence. Despite this, most patients undergo frequent surveillance neck ultrasound (US). The objective of the study was to evaluate the clinical utility of routine neck US in ATA low-risk PTC patients with no structural evidence of disease after their initial thyroid surgery.
METHODS: We performed a retrospective review of 171 ATA low-risk PTC patients after total thyroidectomy, with or without radioactive iodine (RAI) ablation, who had a neck US without suspicious findings after therapy. The main outcome measure was a comparison of the frequency of finding false-positive US abnormalities and the frequency of identifying structural disease recurrence.
RESULTS: Over a median follow-up of 8 years, 171 patients underwent a median of 5 neck US (range 2-17). Structural recurrence with low-volume disease (≤1 cm) was identified in 1.2% (2/171) of patients at a median of 2.8 years (range 1.6-4.1 years) after their initial diagnosis. Recurrence was associated with rising serum thyroglobulin (Tg) level in 1 of the 2 patients and was detected without signs of biochemical recurrence in the other patient. Conversely, false-positive US abnormalities were identified in 67% (114/171) of patients after therapy, leading to additional testing without identifying clinically significant disease.
CONCLUSION: In ATA low-risk patients without structural evidence of disease on initial surveillance evaluation, routine screening US is substantially more likely to identify false-positive results than clinically significant structural disease recurrence.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26372300      PMCID: PMC5027141          DOI: 10.4158/EP15851.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  17 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

2.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

3.  Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer.

Authors:  Sophie Leboulleux; Elizabeth Girard; Mathieu Rose; Jean Paul Travagli; Nadia Sabbah; Bernard Caillou; Dana M Hartl; Nathalie Lassau; Eric Baudin; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2007-07-03       Impact factor: 5.958

Review 4.  Sonographic imaging of thyroid nodules and cervical lymph nodes.

Authors:  Stephanie A Fish; Jill E Langer; Susan J Mandel
Journal:  Endocrinol Metab Clin North Am       Date:  2008-06       Impact factor: 4.741

5.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

Review 6.  Normal and abnormal sonographic findings at the thyroidectomy sites in postoperative patients with thyroid malignancy.

Authors:  Myung-Su Ko; Jeong Hyun Lee; Young Kee Shong; Gyung Yub Gong; Jung Hwan Baek
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

7.  Papillary thyroid cancer: time course of recurrences during postsurgery surveillance.

Authors:  Cosimo Durante; Teresa Montesano; Massimo Torlontano; Marco Attard; Fabio Monzani; Salvatore Tumino; Giuseppe Costante; Domenico Meringolo; Rocco Bruno; Fabiana Trulli; Michela Massa; Adele Maniglia; Rosaria D'Apollo; Laura Giacomelli; Giuseppe Ronga; Sebastiano Filetti
Journal:  J Clin Endocrinol Metab       Date:  2013-01-04       Impact factor: 5.958

8.  An observational trial for papillary thyroid microcarcinoma in Japanese patients.

Authors:  Yasuhiro Ito; Akira Miyauchi; Hiroyuki Inoue; Mitsuhiro Fukushima; Minoru Kihara; Takuya Higashiyama; Chisato Tomoda; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

9.  Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients.

Authors:  E Robenshtok; S Fish; A Bach; Jose M Domínguez; A Shaha; R M Tuttle
Journal:  J Clin Endocrinol Metab       Date:  2012-05-25       Impact factor: 5.958

10.  Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation.

Authors:  Samantha Peiling Yang; Ariadne M Bach; R Michael Tuttle; Stephanie A Fish
Journal:  J Clin Endocrinol Metab       Date:  2015-01-29       Impact factor: 5.958

View more
  6 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

2.  Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?

Authors:  Luca Giovanella; Anca M Avram; Jerome Clerc; Elif Hindié; David Taïeb; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-30       Impact factor: 9.236

3.  Computed tomographic features of the proximal petrous facial nerve canal in recurrent Bell's palsy.

Authors:  Philip Touska; Cristina Dudau; Janki Patel; Antanas Montvila; Milda Pucetaite; Rupert Obholzer; Irumee Pai; Steve Connor
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-06-09

4.  Physician Confidence in Neck Ultrasonography for Surveillance of Differentiated Thyroid Cancer Recurrence.

Authors:  Kevin J Kovatch; David Reyes-Gastelum; Jennifer A Sipos; Elaine M Caoili; Ann S Hamilton; Kevin C Ward; Megan R Haymart
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-12-23       Impact factor: 6.223

Review 5.  Routine thyroglobulin, neck ultrasound and physical examination in the routine follow up of patients with differentiated thyroid cancer-Where is the evidence?

Authors:  Jessica L Gray; Gautam Singh; Lesley Uttley; Saba P Balasubramanian
Journal:  Endocrine       Date:  2018-08-20       Impact factor: 3.633

Review 6.  Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts.

Authors:  Alfredo Campennì; Daniele Barbaro; Marco Guzzo; Francesca Capoccetti; Luca Giovanella
Journal:  Endocrine       Date:  2020-08-09       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.